Danaher Corporation

Danaher provides equipment, supplies, software and services that drug makers, research scientists and medical testing labs use. It runs more than 15 operating companies grouped into three segments, has facilities in about 50 countries, and reaches customers mainly through its own sales force. It grew largely through acquisitions, including Beckman Coulter in 2011, Pall in 2015, Cytiva in 2020 and Abcam in 2023. Each business follows the Danaher Business System, a shared set of continuous-improvement tools and management habits.

Diagnostics was the largest segment in 2025, at 40.5% of $24.6 billion in sales. Life Sciences, at 29.9%, offers lab instruments such as mass spectrometers (machines that identify molecules) and microscopes, plus antibodies and custom DNA and RNA for research. Biotechnology, at 29.7%, operates under the Cytiva and Pall brands. It supplies filters, cell-growth liquids, single-use equipment and services that drug companies use to develop and make biological medicines such as antibody drugs, vaccines and gene therapies.

Most revenue is repeat business. In 2025, 81.9% of sales were recurring, meaning products and services customers typically order again and again, which tends to be steadier than one-time purchases. By region, North America provided 42.2% of sales (the United States alone 41%), high-growth markets such as Asia, Latin America and Eastern Europe 28.6%, and Western Europe 24.2%.

• In Q3 FY2026 (ended Sep 25, 2026), revenue was $6.55B, up 8.3% from a year earlier, and net income was $1.24B (+36.0%).
• For fiscal 2025, revenue was $24.57B (+2.9% year over year; -0.2% a year from FY2021 to FY2025) with a 14.7% net margin.

• Over FY2021–FY2025: $9.07B in buybacks and $4.03B in dividends.
• Regular dividend per share increased 1 years in a row.
• Regular dividends per share grew +7.5% a year over 5 years (FY2020–FY2025).
• Dividends took 24.3% of earnings and 16.7% of free cash flow in the latest fiscal year.
• Shares outstanding changed -1.7% from Feb 4, 2022 to Oct 15, 2026.

Rank among 1514 US companies

Market value at each year end

Danaher’s market value went from $53.84B at the end of 2016 to $160.38B on Nov 2, 2026, about 3.0 times as much; since the end of 2025 it is down 1%.

Form 4 filings from 2025-11-03 to 2026-11-03 (25 read): 0 open-market purchases and 7 sales ($21.5M).

Large shareholders (13G filings)

ETFs with the most weight in DHR

1. Growth leans heavily on acquisitions. Danaher grew through deals such as Cytiva and Abcam. If it can't acquire companies at sensible prices, or integrates them poorly, growth can slow and past purchases may need write-downs that cut reported earnings.
2. Possible tax bill from past separations. Danaher has separated Fortive, Envista and Veralto from the company. If tax authorities later decide any of those deals was a taxable transaction, Danaher could face a significant liability.
3. Customer markets can shrink or cycle. Danaher's customers are mainly drug makers, biotech firms, research labs and diagnostics users. If those markets shrink, grow more slowly than expected or move in cycles, demand for its products can fall.
4. Strict FDA and overseas health rules. Several Danaher businesses must follow US Food and Drug Administration rules and similar rules abroad. Some product changes need a new 510(k) clearance, the FDA's premarket review. Lapses can mean recalls, halted sales or penalties.
5. Pressure from healthcare cost-cutting. Governments and private companies keep pushing to cut healthcare costs. That puts pressure on what customers will pay and favors cheaper, more efficient products, which can squeeze Danaher's prices and margins.
6. Heavy reliance on sales outside the US. Only 41% of 2025 sales were in the United States, and 28.6% came from high-growth markets such as Asia. Trade barriers, policies favoring local suppliers, wars and currency swings can hurt sales and profits.

• Oct 21, 2026 Quarterly results released
• Oct 13, 2026 Executive or board change; Other company announcement
• Aug 3, 2026 Executive or board change; Investor presentation or announcement; Other company announcement
• Jul 21, 2026 Quarterly results released
• Jun 3, 2026 New debt or financial obligation; Other company announcement
• May 7, 2026 Executive or board change; Shareholder vote results
• Apr 29, 2026 Major agreement signed; Other company announcement
• Apr 21, 2026 Quarterly results released
• Apr 17, 2026 Major agreement signed; New debt or financial obligation
• Feb 17, 2026 Other company announcement

Danaher pays a small dividend, so investors would rely mostly on share-price growth rather than income: the yield was 0.66% as of October 27, 2026. It paid $1.23 per share for 2025, up from $0.86 in 2020, or about 7.5% a year. But the per-share amount dipped in 2023 and 2024, so the streak of yearly increases is one year. The dividend used 24.3% of 2025 earnings and 16.7% of free cash flow (cash left after investing in the business). Danaher has favored buybacks, spending $9.1 billion on them from 2021 to 2025, against $4.0 billion in dividends.

In past market downturns the shares fell hard. They dropped 45.8% in the 2008 financial crisis and took about 20 months to recover. They fell 25.9% in the 2020 COVID crash and regained the loss in about a month. In the 2022 bear market they lost 24.8% and needed almost 27 months to recover. Single stocks carry more risk than diversified funds.